In vitro inhibition of fatty acid synthase by 1,2,3,4,6-penta-O-galloyl-β-d-glucose plays a vital role in anti-tumour activity

1,2,3,4,6-Penta-O-galloyl-β-d-glucose(PGG) specifically target fatty acid synthase for cancer therapy by being transported across cancer cell membranes, inhibiting FAS expression and activating caspase in cancer cells by competition with Mal-CoA or NADPH without inducing conformational changes or the precipitation of FAS.